Re: Leclercq et al.: Anti-tumor necrosis factor-alpha versus tocilizumab in the treatment of refractory uveitic macular edema: a multicenter study from the French Uveitis Network (Ophthalmology. 2022;129:520-529) REPLY

Author(s):
Gelmi, M.C. (0000-0002-9099-009X); Bas, Z.; Malkani, K.; Ganguly, A.; Shields, C.L.; Jager, M.J. (0000-0003-2261-3820)
Published
2022
Publication type
Article / Letter to editor
Date issued
2022-07-01
Language
English
Publisher
ELSEVIER SCIENCE INC
Is part of
hdl
1887/3485617